Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170513 | 1.00 | ACE (0.57) | ACEPTPN1MMECPA1ACE2 | |
| SCHEMBL3925164 | 0.87 | ACE (0.55) | ACEPTPN1CTSSCTSKSCN9A | |
| SCHEMBL2781125 | 0.86 | MME (0.60) | ACEMMECPA1ACE2KMT2A | |
| SCHEMBL2780274 | 0.86 | MME (0.60) | ACEMMECPA1ACE2KMT2A | |
| SCHEMBL6156362 | 0.85 | ACE (0.58) | ACEPTPN1CTSSCTSKSCN9A | |
| SCHEMBL4117148 | 0.85 | ACE (0.58) | ACEPTPN1CTSSCTSKSCN9A | |
| SCHEMBL269930 | 0.85 | ACE (0.58) | ACEPTPN1CTSSCTSKSCN9A | |
| SCHEMBL13541332 | 0.85 | ACE (0.58) | ACEPTPN1CTSSCTSKSCN9A | |
| SCHEMBL269929 | 0.85 | ACE (0.58) | ACEPTPN1CTSSCTSKSCN9A | |
| SCHEMBL873556 | 0.85 | ACE (0.58) | ACEPTPN1CTSSCTSKSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445678-B2 | 2-quinoxalinol salen compounds and uses thereof | AUBURN UNIVERSITY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120028362-A1 | 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF | AUBURN UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20090286968-A1 | 2-Quinoxalinol Salen Compounds and Uses Thereof | AUBURN UNIVERSITY (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286968-A1 | 2-Quinoxalinol Salen Compounds and Uses Thereof | NQO1, NQO2, SQOR | ACE 1254/4885PTPN1 4172/4885MME 4369/4885 |
| US-20120028362-A1 | 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF | NQO1, NQO2, SQOR | ACE 1254/4885PTPN1 4172/4885MME 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.